Craig Lindsley Archives
Lindsley named fellow of National Academy of Inventors
Jan. 4, 2019—Craig Lindsley, co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been named a fellow of the National Academy of Inventors.
What’s On My Mind: The bright points of 2018
Dec. 21, 2018—Chancellor Nicholas S. Zeppos reflects on Vanderbilt's work, progress and accomplishments over the past 12 months in his final column of 2018.
Lindsley named to National Academy of Inventors
Dec. 11, 2018—Craig W. Lindsley, William K. Warren Jr. Professor of Medicine and co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been elected a fellow of the prestigious National Academy of Inventors.
Ancora announces major funding awards to support Vanderbilt drug discovery research
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
AAAS, chemistry society honor Lindsley’s research contributions
Feb. 1, 2018—Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS).
Vanderbilt researchers’ papers among those most cited
Dec. 7, 2017—Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Lindsley honored by Pharmaceutical Society of Japan
Dec. 7, 2017—Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.
University of Kansas honors Lindsley’s pharmacology research
Sep. 21, 2017—Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Vanderbilt, Ono Pharmaceutical extend drug discovery agreement
May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
Lindsley’s drug discovery efforts land ASPET Award
Jan. 12, 2017—Craig Lindsley, Ph.D., a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is the 2017 recipient of the Pharmacia-ASPET Award in Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.